Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
November 01, 2018 02:00 ET
|
Denali Therapeutics Inc.
Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseasesDenali to receive...
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
October 03, 2018 09:00 ET
|
Denali Therapeutics Inc.
ROSTOCK, Germany and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global...
Denali Therapeutics Reports Second Quarter 2018 Financial Results
August 09, 2018 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer
August 07, 2018 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinson’s Disease
August 01, 2018 16:30 ET
|
Denali Therapeutics Inc.
Healthy volunteer study of DNL201 meets all objectives in phase 1 clinical study, including CSF exposure levels and LRRK2 inhibition, as well as pathway engagement, at doses that were safe and well...
Denali Therapeutics Announces Early Exercise of Its Option to Acquire F-star Gamma
May 30, 2018 16:05 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, May 30, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative...
Denali Therapeutics Reports First Quarter 2018 Financial Results
May 11, 2018 08:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for...
Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights
March 19, 2018 08:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for...
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
February 08, 2018 09:00 ET
|
Denali Therapeutics Inc.; Lonza Pharma & Biotech
Partnership aims to develop drugs for neurodegenerative diseasesDenali will draw on Lonza’s expertise in developing and manufacturing complex biologic molecules BASEL, Switzerland and SOUTH SAN...
Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s Disease
December 20, 2017 17:50 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for...